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Abstract 
The morbidity and mortality from cardiovascular diseases (CVD) remain high. 
Metabolic diseases such as obesity, hyperlipidemia, diabetes mellitus (DM), non-
alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) as 
well as hypertension are the most common comorbidities in patients with CVD. These 
comorbidities result in increased myocardial oxidative stress, mainly from increased 
activity of nicotinamide adenine dinucleotide phosphate oxidases, uncoupled 
endothelial nitric oxide synthase, mitochondria as well as downregulation of 
antioxidant defense systems. Oxidative and nitrosative stress play an important role in 
ischemia/reperfusion injury and may account for increased susceptibility of the 
myocardium to infarction with one or several of the above comorbidities. On the other 
hand, controlled release of reactive oxygen  species is also important for 
cardioprotective signaling. In this review we summarize the current data on the effect 
of hypertension and major cardiometabolic comorbidities such as obesity, 
hyperlipidemia, DM, NAFLD/NASH on cardiac redox homeostasis as well as on 
ischemia/reperfusion injury and cardioprotection. We also review and discuss the 
therapeutic interventions that may restore the redox imbalance in the diseased 
myocardium in the presence of these comorbidities.  
Keywords: cardiovascular comorbidities; oxidative stress; myocardial infarction; 
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Abbreviations 
AGE  advanced glycation end-products 
AMPK  AMP-activated protein kinase 
Apo  apoprotein 
BH4  tetrahydrobiopterin 
BMI  body mass index 
CAMK-II calmodulin-dependent kinase-II 
CAT  catalase 
CR  caloric restriction 
CVD  cardiovascular disease 
DAMP  damage-associated molecular patterns 
DHA  docosahexaenoic acid 
DM  diabetes mellitus 
DPP  dipeptidyl protease 
eNOS  endothelial nitric oxide synthase 
EPA  eicosapentaenoic acid 
ERK  extracellular signal regulated kinase  
ETC  electron transport chain 
FMD  flow-mediated dilatation 
FOXO  forkhead box protein O 
GLP-1  glucagon-like peptide-1 
GPx  glutathione peroxidase 
GR  glutathione reductase 
GSH  reduced glutathione 
GSK-3  glycogen synthase kinase-3  
GSSG  oxidized glutathione 
GST  glutathione transferase 
HF  heart failure 
HIF  hypoxia inducible factor 
HKII  hexokinase-II  
Andreadou et al.  comorbidities and cardioprotection  5 
H2S  hydrogen sulfide 
HSP  heat shock protein 
IHD  ischemic heart disease 
IL  interleukin 
iNOS  inducible nitric oxide synthase 
IRI  ischemia/reperfusion injury 
KO  (gene) knockout (mouse strain) 
LDL  low-density lipoprotein 
LV  left ventricle 
LVH  left ventricular hypertrophy 
MAO  monoamine oxidase 
MAPK  mitogen-activated protein kinase 
MI  myocardial infarction 
mPTP  mitochondrial permeability transition pore 
3-MST  3-mercaptopyruvate sulfurtransferase 
NADPH reduced nicotinamide adenine dinucleotide phosphate 
NAFLD non-alcoholic fatty liver disease 
NASH  non-alcoholic steatohepatitis 
NFAT  nuclear factor of activated T-cells 
NF B  nuclear factor-kappa B  
NNT  nicotinamide nucleotide transhydrogenase 
NO  nitric oxide 
NOX  nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 
Nrf-2  nuclear factor erythroid 2-related factor 
NSTEMI non-ST elevation myocardial infarction 
OSE  oxidation specific epitopes 
Ox-LDL oxidised low-density lipoprotein (LDL) 
PCSK9 proprotein convertase subtilisin/kexin type 9 
PDE5  phosphodiesterase-5 
PGC  peroxisome proliferator activated receptor-gamma (PPAR- ) 
coactivator  
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PKC  protein kinase C 
PKG  cyclic guanosine monophosphate (cGMP)-dependent kinase 
Pon  paraoxonase 
PPAR  peroxisome proliferator activated receptor 
Prdx  peroxiredoxin 
PUFA  polyunsaturated fatty acid 
RAGE  receptor of advanced glycation end-products (AGE) 
RNS  reactive nitrogen species 
ROS  reactive oxygen species 
SGLT2 sodium-glucose cotransporter-2 
SIRT  sirtuin 
sNox2-dp soluble NOX2-derived peptide 
SOD  superoxide dismutase 
SphK1  sphingosine kinase-1 
STEMI ST-elevation myocardial infarction 
STZ  streptozotocin 
T2DM  type-2 diabetes mellitus 
TNF   tumor necrosis factor-alpha 
Trx  thioredoxin 
UCP  uncoupling protein 
VSMC  vascular smooth muscle cells 
XO  xanthine oxidase 
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1. Introduction 
Cardiovascular diseases (CVD) are the leading causes of disease burden and the 
primary causes of death worldwide [1]. CVD are systemic diseases, rarely occurring 
alone so it is common to find multiple comorbid conditions in the setting of CVD, 
particularly in the elderly population. Comorbidities, the presence of one or more 
chronic diseases among patients with CVD, are increasing due to reduced case fatality 
of ischemic heart disease (IHD) and prolonged life expectancy [2, 3]. However, the 
rising prevalence of diabetes mellitus (DM) worldwide, linked to the almost ubiquitous 
increase of obesity and non-alcoholic fatty liver disease and steatohepatitis (NAFLD 
and NASH) globally, is mitigating reductions in the burden of CVD by effective 
cardiological interventions (cholesterol and blood pressure lowering, coronary 
interventions, etc.). Metabolic diseases such as obesity, hyperlipidemia, DM, NAFLD 
and NASH as well as hypertension are common comorbidities in patients with IHD and 
heart failure (HF) and affect the clinical outcomes profoundly [4]. 
Obesity and DM synergistically cause myocardial dysfunction independent of 
coronary artery disease and hypertension since both conditions share similar 
pathophysiological mechanisms [5, 6]. Similarly, hyperlipidemia per se is able to 
negatively affect myocardial function. These metabolic heart diseases (myocardial 
dysfunction caused by obesity, hyperlipidemia, and DM) are characterized by altered 
myocardial energetics with mitochondrial dysfunction, nitro-oxidative stress, abnormal 
cellular metabolism leading to lipotoxicity in the myocytes, cardiac autonomic 
neuropathy, as well as increased inflammation and interstitial collagen deposition [7-
9]. These pathological changes 1. are further aggravated by the parallel development of 
coronary atherosclerosis; 2. result in subclinical myocardial dysfunction (initially 
diastolic) and eventually the development of overt HF with preserved ejection fraction 
that may over time progress into HF with reduced ejection fraction [10]; and 3. exert 
numerous biochemical effects on the heart that negatively affect the development of 
ischemia/reperfusion injury (IRI) and interfere with cardioprotective interventions, 
notably ischemic conditioning. However, the exact mechanism by which the 
remarkable cardioprotective effect of ischemic conditioning is attenuated or abolished 
in the presence of major cardiovascular risk factors and comorbidities is not fully 
understood [11]. Accentuated myocardial oxidative stress has been reported in the 
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presence of major comorbidities (Figure 1); therefore, it is plausible that redox 
signaling-dependent changes profoundly contribute to the pathological phenotypes.  
In this review we summarize the current data on the effect of major cardiovascular 
comorbidities on cardiac redox homeostasis, focusing on metabolic diseases such as 
obesity, hyperlipidemia, DM, hypertension and NAFLD/NASH. We will also review 
the therapeutic interventions that may restore the redox imbalance in the diseased 
myocardium in presence of these comorbidities. 
 
2. Obesity 
According to WHO data for 2014, 11% of men and 15% of women (>18 years old) 
were obese (body mass index [BMI] > 30 kg/m2) [12]. More than 42 million children 
under the age of 5 years were reported to be overweight in 2013. Obesity increases the 
risk of myocardial infarction (MI) by 20-40% (odds ratio 1.2-1.4 in different studies). 
High BMI is ranked fifth among the leading risk factors for disability-adjusted life years 
(years lived with severe illness) based on the global burden of disease data for 2019 
[13]. Obesity is strongly associated with the development of atherosclerosis, but it may 
also have direct effects on the heart [14]. Results from the Framingham Heart Study 
indicated that increased BMI correlates well with greater risk for developing HF both 
in men and women [10]. Data from patients and animal models clearly indicate that the 
heart undergoes structural and functional changes in obesity [14]. Hearts from obese 
subjects have increased left and right ventricular wall thickness, increased left atrium 
dimensions, fibrosis and accumulation of intracellular triglycerides [14]. Subclinical 
contractile alterations have been detected in obese patients, along with diastolic 
dysfunction [14, 15]. Similar results have been observed in experimental models of 
obesity, suggesting that obesity alone does not cause impairment in systolic function, 
although it does affect cardiac relaxation properties [16-18].  
Increased circulating free fatty acids trigger a vicious cycle harming the antioxidant 
response in overweight and obese individuals [19, 20]. This is particularly true for the 
myocardium under stress conditions;  glucose, compared with fatty acids, is the more 
efficient substrate to boost high energy products with respect to oxygen consumption 
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[21]. Despite these evident repercussions on cardiac structure and function in obesity, 
it is challenging to distinguish between the effects deriving directly from obesity and 
the effects of other comorbidities strongly associated with obesity, such as 
atherosclerosis, hypertension, hyperlipidemia and DM.  
2.1.  Obesity and Redox signaling in myocardial infarction 
A number of studies have highlighted an increased myocardial susceptibility to IRI in 
experimental models of obesity and in patients [22-26]. However, other studies report 
conflicting results, such as normal or even enhanced functional recovery following 
ischemia/reperfusion in obese animals [27-29]. The reason for this discrepancy is not 
clear. One possibility is that changes in hemodynamics (i.e. preload and afterload) may 
confound contractile defects in vivo [14]. In addition, obesity is associated with elevated 
circulating concentrations of insulin and fatty acids that might affect the extent of 
myocardial damage after IRI [30-32]. Indeed, one study found that obesity led to 
increased infarct size and reduced functional recovery after ischemia/reperfusion 
performed ex vivo with the classic Krebs-Henseleit perfusion buffer, but the presence 
of insulin and fatty acids in the buffer completely abolished these differences between 
obese and non-obese hearts [22]. An additional factor that may affect the outcome is 
age, since aged obese hearts show reduced functional recovery when subjected to 
preconditioning [33]. 
From a molecular standpoint, changes in substrate utilization, mitochondrial 
function, redox signaling and inflammation occur much earlier and precede measurable 
changes in cardiac function in obese hearts. The functional recovery of the heart after 
ischemia/reperfusion can be improved by increasing glucose oxidation during 
reperfusion [32]. Unsurprisingly, increased delivery of fatty acids in obese hearts and 
activation of related pathways, such as peroxisome proliferator-activated receptor alpha 
(PPAR ), contribute to myocardial degeneration [14]. A common denominator in these 
metabolic alterations is oxidative stress. BMI was directly correlated with several 
oxidative stress parameters, positively with p47phox expression and hydroethidium 
oxidation, but negatively correlated with endothelial nitric oxide synthase (eNOS) 
phosphorylation and dihydrofolate reductase expression in patients undergoing 
coronary artery bypass graft surgery [34]. In patients with IHD, BMI also correlated 
with leptin levels and oxidative stress markers, with an impact on cardiovascular and 
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operative risk profiles [35]. The coexistence of hypercholesterolemia and obesity in 
children caused additive increase of 8-isoprostanes and soluble nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase (NOX) 2-derived peptide (sNox2-dp, a 
marker of NOX2 activation) and additive impairment of endothelial function measured 
by flow-mediated dilation (FMD) [36]. Obesity is associated with alterations in 
mitochondrial function, number and turnover [37-40]; thus, impairment in 
mitochondrial oxidative capacity observed in ob/ob mice inevitably results in increased 
superoxide formation [14]. Indeed, the mitochondrial respiratory chain (i.e. complexes 
I and III) is considered the most relevant source of reactive oxygen species (ROS) in 
obese or diabetic hearts [41]. An additional mechanism for mitochondrial ROS 
formation is represented by p66Shc that, upon phosphorylation by protein kinase C 
(PKC), translocates to mitochondria to induce hydrogen peroxide (H2O2) formation 
[42]. p66Shc is critical for insulin signaling and glucose uptake and its phosphorylation 
is increased in obesity and DM [43, 44]. Moreover, its deletion reduces oxidative stress 
and atherogenesis in mice fed with high-fat diet [45].  
Besides mitochondria, other enzymes within the cell contribute to the alteration 
of redox equilibrium and there may be crosstalk between them. For instance, p66Shc 
inhibits forkhead-box-protein O (FOXO) transcription factors in the nucleus thereby 
affecting the expression of antioxidant enzymes [46]. Importantly, p66Shc can also 
activate ras-related C3 botulinum toxin substrate 1 (rac1) and trigger NOX mediated 
ROS formation [46]. Indeed, NOX activity is enhanced in obese animals and its 
inhibition prevents oxidative stress and impairment in cardiac function in these hearts 
[47, 48]. Both mitochondrial and NOX-dependent ROS formation play a major role in 
lipotoxicity. Obese patients have higher circulating levels of saturated fatty acid 
palmitate that can trigger mitochondrial ROS formation. This can in turn be amplified 
by NOX2 causing mitochondrial dysfunction and further amplifying oxidative stress in 
a vicious cycle [49]. Furthermore, the inability of cardiomyocytes to respond to an 
increased fatty acid load results in the generation of toxic lipid intermediates, such as 
ceramide, that promote mitochondrial dysfunction and cell death [48, 50]. Lipotoxicity 
further aggravates cardiac IRI and mitochondrial ROS play a major role in this 
mechanism [51, 52]. Indeed, it has been demonstrated that ROS produced by the 
mitochondrial flavoenzyme monoamine oxidase A (MAO-A) inhibit sphingosine 
kinase-1 (SphK1) and are associated with generation of proapoptotic ceramide. It is 
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noteworthy that SphK1 inhibition, ceramide accumulation, infarct size and 
cardiomyocyte apoptosis were significantly decreased in MAO-A deficient animals 
subjected to IRI [52]. MAO plays a major role in the oxidative stress in diabetic 
cardiomyopathy [53] and it remains to be elucidated whether these mechanisms also 
apply to changes observed in obese hearts. Interestingly, the selective MAO-B 
inhibitor, selegiline, was able to reduce adiposity and improve metabolic parameters in 
a rat model of diet-induced obesity [54].  
Among other sources of ROS in the heart, xanthine oxidase (XO) has been shown 
to promote oxidative stress, inflammation and alterations in cardiac structure and 
function in mice fed a Western diet [55]. On the other hand, antioxidant enzymes also 
play a major role in obese hearts. For instance, expression and/or activity of many 
antioxidant enzymes is reduced in cardiac tissue or in the circulation of obese animals 
[48]. Moreover, mitochondrial peroxidases involved in ROS removal use NADPH 
provided mostly by nicotinamide nucleotide transhydrogenase (NNT). A recent study 
showed that, in conditions of high nutrient availability and low energy demand, NNT 
activity maintains low ROS levels through a fine modulation of mitochondrial oxygen 
utilization [56]. In failing hearts, NNT activity can be reversed resulting in the depletion 
of mitochondrial antioxidant capacity and oxidative stress [57]. Yet, whether alterations 
in NNT activity may be responsible for altered redox equilibrium in obese and ischemic 
hearts has not been investigated to date. 
2.2. Pharmacological redox modulation in obesity and cardioprotection 
Lifestyle intervention, caloric restriction (CR), exercise training and different 
pharmaceutics/nutraceuticals have been proposed to limit the inflammatory response 
and ROS generation and to improve the antioxidant machinery in obesity. -3-
polyunsaturated fatty acids (PUFAs) are broadly used as a secondary interventional 
approach in CVD and have been extensively investigated in the setting of obesity. In 
vitro studies have shown that PUFAs interfere with eicosanoid generation [58] and 
decrease NOX activity [59]. Eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA) administration increased the expression of heme oxygenase-1 by a mechanism 
dependent on nuclear factor erythroid 2-related factor 2 (Nrf-2) [60]. Moreover, PUFA 
supplementation in humans resulted in increased expression of antioxidants such as 
catalase (CAT), heme oxygenase-2, glutathione transferases (GST) and glutathione 
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reductase (GR) and in the down regulation of pro-oxidant genes such as the glutathione 
peroxidases [61]. In addition to PUFAs, polyphenols were found to boost nitric oxide 
(NO) bioavailability by inducing eNOS activity, while reducing NOX1 in obese 
animals [62]. Long term resveratrol administration, besides increasing the expression 
of eNOS in white adipose tissues, reduces the systemic inflammatory response by 
increasing the circulating levels of adiponectin and lowering the release of tumor 
necrosis factor-alpha  [63]. Mechanistically, these compounds were found to 
exert their anti-inflammatory and cardioprotective effects by activating the adenosine 
monophosphate (AMP)-activated protein kinase (AMPK), peroxisome proliferator-
activated receptor gamma coactivator (PGC)- - -mediated pathways in 
Zucker Diabetic Fatty (ZDF) rats [63]-[64].  
A number of primary and secondary interventional studies have reported the 
benefit of CR, indicating that CR is effective in reducing the anti-inflammatory 
response and in improving the antioxidant response in obese individuals [65]. In 
particular, CR-mediated protection relies on the decrease of oxidative stress markers 
via sirtuins (SIRT), NAD+-dependent deacetylases [66]-[67], FOXO [68] and PGC-1 -
mediated mitochondrial bioenergetics [69]. CR can additionally exert cardioprotection 
by induction of antioxidant adaptive genes associated to the increased expression of 
adiponectin and the activation of the AMPK [70]. It was also noticed that CR-mediated 
cardioprotection occurs via SIRT1 and PGC-1  in obese animals [71]. Polyphenols and 
exercise training were reported to induce stress response genes and mitochondrial 
biogenesis via AMPK and SIRT mediated reduction of FOXO activity [72]-[73]. Of 
note, prebiotics, probiotics, and synbiotics were found to induce cardioprotection by 
restoring mitochondrial dysfunction via the improvement of the electromechanical 
proton gradient in obese animals [74]. 
An improvement of mitochondrial biogenesis and myocardial function in obese 
transgenic mice overexpressing mitochondrial-CAT has been demonstrated, an effect 
relying on the decrease of ROS generation in the heart [75]. Lowell et al. first 
demonstrated the role of mitochondrial uncoupling in driving obesity [76]. Partial 
mitochondrial uncoupling improving post-ischemic functional recovery via a ROS-
dependent pathway has been observed [77]. SIRT1 [78] and PPAR  pathways were 
recently found to drive white-to-brown adipose tissue remodelling via uncoupling 
proteins (UCP) such as UCP1 [79]. Mild uncoupling of oxidative phosphorylation is 
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one of the mechanisms suggested to be cardioprotective as chemical uncoupling mimics 
ischemic preconditioning and of note, chemical uncouplers acting on mitochondrial 
H2O2 production in the heart, share common cardioprotective mechanisms with low 
concentrations of dietary polyphenols [80]. Mechanistically the UCP3-mediated 
cardio-protection against IRI may involve the inhibition of the mitochondrial 
permeability transition pore (mPTP) opening, mitochondrial calcium overload and ROS 
generation [81].  
Obesity abolishes pharmacological preconditioning-induced cardioprotection 
due to impairment of the ROS-mediated AMPK pathway, a consequence of increased 
basal myocardial oxidative stress. Exercise training can prevent the attenuation of 
anesthetic cardioprotection in obesity by a mechanism including reduced basal 
oxidative stress and normalized ROS-mediated AMPK pathway [82].  
In preclinical models of obesity, cardioprotection was also reported with several 
currently used antidiabetic drugs. Vildagliptin was found to be protective against IRI in 
obese-insulin resistant rats by improving mitochondrial function, oxidative stress and 
apoptosis in the ischemic myocardium [83]. The sodium-glucose cotransporter-2 
(SGLT2) inhibitor dapagliflozin was also found to exert cardioprotection in high-fat 
diet-induced obese/insulin-resistant rats by decreasing the cleaved caspase 3 as well as 
mitochondrial anti-dynamin related protein-1, suggesting a role of dapagliflozin in the 
control of mitochondrial fission [84]. Empagliflozin reduced body weight, infarct size 
and improved redox regulation by decreasing inducible NOS (iNOS) expression and 
subsequently lipid peroxidation in mice fed a Western diet [85].  
Adiponectin has been reported to play a protective role in the development of 
obesity-linked disorders. It has been shown that adiponectin protects against IRI in a 
pig model through its ability to suppress inflammation, apoptosis and oxidative stress 
[86]. Treatment with AC261066, a synthetic selective agonist for the retinoic acid 2- 
receptor exerted protective effects in obese (high fat diet-fed) wild-type mice when their 
hearts were subjected to ischemia/reperfusion ex vivo. This cardioprotection was 
associated with decreased formation of ROS and toxic aldehydes [87]. Melatonin, a 
potent free radical scavenger and antioxidant reduced infarct size in a rat model of diet-
induced obesity and prevented the metabolic abnormalities induced by diet-induced 
obesity [88]. MitoTEMPO, a mitochondria-targeted ROS scavenger, prevented cardiac 
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fibrosis and oxidative stress and ameliorated weight gain in a high fat diet rodent model 
[89]. Similar protective effects were observed with mitoQ, a synthetic mitochondrial 
antioxidant [90-92]. 
In summary, although it is difficult to separate the effects originating only 
from obesity from the effects induced by other comorbidities strongly associated 
with obesity, such as hyperlipidemia and diabetes, redox signaling triggers 
changes in cardiac function in obese hearts. Lowering oxidative stress to prevent 
metabolic disorders related to obesity constitutes to be an interesting therapeutic 
target. However, further studies are needed to clearly understand ROS 
generation, typology, and distribution in obesity. 
 
3. Hyperlipidemia 
According to WHO data, the global prevalence of hyperlipidemia 
(hypercholesterolemia) could be up to 40% [93]. Hyperlipidemia increases the risk of 
MI more than 8-fold (odds ratio 8.39) [94]. Low density lipoprotein (LDL) cholesterol 
is ranked eighth among the leading risk factors for disability-adjusted life years (years 
lived with severe illness) based on the global burden of disease data of the year 2019 
[13]. Multiple experimental studies have shown that hyperlipidemia enhances infarct 
size and favors cardiolipotoxicity. Oxidative stress and NO play an important role in 
LDL accumulation in the vascular wall [95]. Hypercholesterolemia facilitates the 
reaction between ROS and NO inducing the generation of reactive nitrogen species 
(RNS) such as dinitrogen trioxide (N2O3) and peroxynitrite [96]. Nitrosation of protein 
thiols by peroxynitrite may also exert detrimental effects on protein synthesis 
contributing to the promotion of ROS and inflammation [97]. Both native LDL and 
oxidized LDL (oxLDL) stimulate superoxide/peroxynitrite production and uncouple 
eNOS [98] thereby reducing endothelial NO production by inhibiting eNOS activity 
[99]. Furthermore, hypercholesterolemia upregulates caveolin and promotes eNOS 
interaction with caveolin [100] and decreases the association of eNOS with heat shock 
protein (HSP) 90 [101] resulting in a further inhibition of eNOS activity. Finally, 
oxLDL decreases eNOS activity either by inhibiting phosphorylation of eNOS at serine 
1177 [102] or by increased proteasomal degradation of eNOS [103]. Consistent with 
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experimental evidence, reduced bioavailability of NO has been demonstrated in 
hypercholesterolemic patients [97] and these patients also displayed impaired 
endothelial function (measured by venous occlusion plethysmography) [104]. Apart 
from the direct effects of lipids on ROS/NO formation, disturbed flow pattern with the 
development of atherosclerosis reduces endothelial NO production [105] and enhances 
ROS production in endothelial cells and in vascular smooth muscle cells (VSMC) 
[106]. Oxidative stress and ROS play opposite roles in the regulation of adhesion 
molecule expression and endothelial leukocyte interaction. Endothelial NO inhibits 
cytokine-induced nuclear factor- B (NFkB) activation and upregulation of vascular cell 
and intercellular adhesion molecules [107, 108], whereas inhibition of NO production 
increases leukocyte adherence [109]. On the contrary, ROS are implicated in 
upregulation of adhesion molecules induced by cytokines [107].   
OxLDL exhibits a wide array of proatherogenic properties and many of these 
effects are mediated by oxidized phospholipids within the LDL molecules. Lipid 
peroxidation can occur through enzymatic mechanisms (e.g., by ROS derived from 
NOX, uncoupled eNOS) [110], myeloperoxidases, lipoxygenases, cyclooxygenases, 
and cytochrome P450). In some cases, ROS formation is based on the original enzyme 
activity, whereas in other cases ROS originate from undesired side reactions. The lipid 
peroxidation products, such as malondialdehyde, 4-hydroxynonenal etc. are highly 
reactive and can lead to the generation of structural neoepitopes termed oxidation-
specific epitopes (OSEs) [111], which play an important role in the development of 
atherosclerosis. OxLDL leads to upregulation of proprotein convertase subtilisin/kexin 
type 9 (PCSK9) expression and release from extrahepatic tissues thereby contributing 
to an increase in the overall circulating PCSK9 concentration, which then impacts on 
LDL levels, but also aggravates atherosclerosis development per se and impairs cardiac 
function [112]-[113]. 
In addition to the direct effects of LDL on endothelial ROS production, 
hypercholesterolemia may indirectly enhance oxidative stress by potentiating the 
effects of angiotensin II via upregulation of angiotensin II type 1 receptor [114]. ROS 
are also produced as byproducts of mitochondrial respiration and can become 
pathologically elevated during metabolic perturbations such as those seen in 
hyperlipidemia [115]. OxLDL inhibits the normal function of mitochondria and thus 
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promotes mitochondrial ROS generation which is in turn involved in LDL oxidation 
creating a vicious cycle. Additionally, ROS may inhibit specific mitochondrial enzymes 
affecting cellular antioxidant and energetic capacities [116].  
3.1.Hyperlipidemia and redox signaling in myocardial infarction 
Hypercholesterolemia increased myocardial necrosis by 45% compared to normal 
animals and this contributed to increased oxidative stress in the ischemic myocardium 
such as protein oxidation, lipid peroxidation, and tyrosine nitration during IRI in the 
setting of hypercholesterolemia [117, 118]. Tyrosine nitration was also increased in 
Watanabe heritable hyperlipidemic rabbits [119]. Accumulating evidence indicates that 
the major enzymatic sources of ROS in the cardiovascular system are NOX, uncoupled 
eNOS, mitochondria and XO [120]. NOX and XO have been proposed to be the major 
sources of superoxide anion in the coronary artery of hypercholesterolemic patients 
with CAD [121] as well as cholesterol-fed rabbits [122]. NOX-derived oxidative stress 
has been shown to be a major mediator of atherosclerosis [123], since LDL oxidation 
can be induced by NOX-derived ROS [124]. As already mentioned above, obesity and 
hypercholesterolemia had additive effects on NOX2 activation (measured by sNox2-
dp) [36] and higher sNox2-dp as well as oxLDL levels were even observed in in 
hypercholesterolemic children [125]. However, the different NOX isoforms seem to 
have different roles in development and progression of atherosclerosis. NOX1 and 
NOX2 are required for the development of atherosclerosis [126]. Deletion of Nox1 in 
apoprotein (Apo)E knockout (KO) mice reduced aortic superoxide production, 
macrophage infiltration and lesion formation [127]. In contrast, several studies have 
shown a protective role of NOX4 in atherosclerosis [128]. Global Nox4 knockout or 
induced deletion of Nox4 increased atherosclerosis in ApoE-KO mice. The results of 
the above-mentioned study demonstrated that H2O2 production was reduced, however, 
increased inflammation, macrophage accumulation and fibrosis were observed in the 
aortae of Nox4/ApoE double KO mice. These data suggest that NOX4-derived H2O2 
might mediate beneficial effects in atherosclerosis via inhibition of inflammation, 
which is contrary to the deleterious effects of ROS produced by NOX1 and NOX2 
[129]. NOX5 is localized in both endothelial and VSMCs and it has been found in the 
coronary arteries from patients with CAD undergoing cardiac transplantation [130]. 
Moreover, NOX5 increases the proliferation of VSMCs [131], but so far, there is no 
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direct evidence available on the role of NOX5 in atherogenesis from animal models 
because rodents do not express NOX5.  
Uncoupling of eNOS is likely to be a subsequent event secondary to oxidative 
stress mediated by NOXs and XO because of oxidation-induced tetrahydrobiopterin 
(BH4) deficiency [132]. Besides BH4 deficiency, L-arginine deficiency also represents 
an underlying cause of eNOS uncoupling in hypercholesterolemia. The latter has been 
supported by studies in ApoE-KO mice and in hyperlipidemic rabbits where 
upregulation of arginase expression and activity caused a decrease in L-arginine levels 
thereby affecting substrate availability for eNOS [133, 134]. ROS derived from 
uncoupled eNOS has been detected in LDL-treated endothelial cells, in 
hypercholesterolemic ApoE-KO mice and in hypercholesterolemic patients as well 
[135]. ROS derived from NOXs and uncoupled eNOS are also involved in the 
generation of OSEs. OSEs, including oxidized phospholipids and malondialdehyde-
modified amino groups, have been documented on the surface of apoptotic cells and 
oxLDL molecules [136]. Peroxidation of phospholipids moieties promotes a change in 
the conformation  of the apoB-100 molecule leading to enhanced nonreceptor-mediated 
capture of oxLDL by vascular cells [136]. Oxidized phospholipids induce the 
expression of chemoattractants and trigger monocyte binding to endothelial cells via 
toll-like receptor 4 [110]. Therefore, OSE sensing by endothelial cells is a key response 
in the development of atherosclerosis [111].  
In addition to the role of ROS in hyperlipidemia, the effects of antioxidant 
defense systems are significant. The expression and activity of antioxidants and 
antioxidant enzymes (especially reduced glutathione, SOD and CAT) in the vascular 
system is reduced in hypercholesterolemia [97]. The effects of SOD on atherogenesis 
are dose-dependent. Moderate SOD1 upregulation reduces ROS burden, whereas 
SOD1 overexpression generates high amount of hydrogen peroxide, which can lead to 
the formation of hydroxyl radicals thereby exacerbating oxidative stress [137]. SOD2 
is one of the first line defense enzymes against superoxide production of the 
mitochondrial electron transport chain (ETC). SOD2 deficiency leads to mitochondrial 
dysfunction and accelerated atherosclerosis in ApoE-KO mice [138]. SOD3 is 
abundantly expressed in the vascular wall and its role in atherogenesis is still unclear. 
Genetic deletion of SOD3 in ApoE-KO mice leads to a slight reduction in 
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atherosclerosis after one-month atherogenic diet, whereas no effect is observed after 
three months [139].  
Glutathione peroxidase (GPx)-1 deficiency increases LDL oxidation, foam cell 
formation, and macrophage proliferation [140]. The protective role of GPx1 against 
atherogenesis has been shown in experimental studies where deficiency of GPx1 
enhanced atherosclerosis in ApoE-KO mice [141, 142]. GPx4 reduces the level of 
hydrogen peroxide and other lipid hydroperoxides, including oxidized phospholipids 
and cholesterol hydroperoxides, and likely explaining why GPx4 overexpression 
reduces atherosclerosis in ApoE-KO mice [143].  
The paraoxonase family proteins (Pon1, Pon2, and Pon3) reduce oxidative 
stress, decrease lipid peroxidation, and diminish atherosclerosis. Pon1 is primarily 
synthesized by the liver and associates with high density lipoprotein (HDL) particles. 
HDL-associated Pon1 inhibits the formation of oxidized phospholipids and therefore 
LDL oxidation [132]. Pon2 is expressed in the vascular wall and in intracellular 
structures, such as the membranes of the endoplasmic reticulum or mitochondria and 
can translocate to the plasma membrane in response to oxidative stress where it 
suppresses lipid peroxidation [144]. Pon2 prevents LDL peroxidation, reduces 
oxidative stress in vascular cells, and protects against atherosclerosis in mouse models 
[145]. Pon2 knockout mice display increased ROS formation and endothelial 
dysfunction as well as higher tissue factor levels and a procoagulant phenotype [146]. 
Pon3 is found both in serum and cells and prevents LDL oxidation like Pon1 [147]. 
Pon2/3 antioxidant effects result from the prevention of mitochondrial superoxide 
formation through an interaction with coenzyme Q10 (ubiquinone) [148]. Pon3 
expression is reduced in vascular cells of atherosclerotic patients [149].  
In contrast to the regulated production of NO by neuronal NOS and eNOS, 
iNOS may generate large amounts of NO over long periods of time and iNOS induction 
in the vasculature facilitates the generation of peroxynitrite [150], a key  
proatherosclerotic  oxidant [151]. Importantly, the expression of iNOS in human 
atherosclerotic plaques is associated with nitrotyrosine staining, a marker of 
peroxynitrite formation [150, 152]. XO also plays a critical role in cholesterol crystal-
induced ROS formation and subsequent inflammatory cytokine release by 
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macrophages. XO inhibition reduces vascular ROS levels, leading to improvement in 
endothelial function, and suppressing plaque formation in ApoE-KO mice [153].  
ROS and RNS production, which may continue for hours after the beginning of 
reperfusion, play an important role in the genesis of reperfusion injury and in the 
recruitment of inflammatory cells [154]. Supplementary to increased ROS/RNS 
production, ischemia/reperfusion also reduces the levels of antioxidant enzymes such 
as glutathione peroxidase, and SOD [155], which are also influenced by the presence 
of hypercholesterolemia as mentioned above. Therefore, in the presence of 
hypercholesterolemia and atherosclerosis ROS/RNS production is unbalanced by cell 
defenses, inducing deleterious effects in a large number of pathways involved in cell 
cycle and survival pathways.  
3.2 Pharmacological redox modulation in hyperlipidemia and cardioprotection 
The increase in ROS generation induced by hypercholesterolemia may interfere with 
endogenous cardioprotective mechanisms such as cardiac preconditioning and 
postconditioning and may have a detrimental role in determining the severity of IRI 
[97]. Therefore, there is an urgent need to better understand the biology and the damage 
caused by ischemia/reperfusion and redox stress in hyperlipidemia before considering 
an appropriate treatment [156].  
The attenuation of nitro-oxidative stress in hyperlipidemic animals has been 
proposed as a cardioprotective mechanism of statins in the setting of myocardial IRI. 
Three-week simvastatin treatment reduced infarct size and reversed the loss of 
postconditioning in hypercholesterolemic rabbits subjected to ischemia/reperfusion by 
attenuation of nitro-oxidative stress in the ischemic myocardium [157]. Short-term 
administration of pravastatin reduced infarction in cholesterol-fed rabbits 
independently of any lipid lowering effect, potentially through eNOS activation and 
attenuation of nitro-oxidative stress [158].  The reduction in infarct size by a natural 
constituent of olives and olive oil, oleuropein, was achieved by attenuation of 
reperfusion injury and reduced oxidative stress in hyperlipidemic rabbits [159].  
Many studies have revealed that HSP70 is induced during myocardial 
ischemia/reperfusion and contributes to cardioprotection by suppression of ROS 
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generation, inhibition of cell apoptosis, attenuation of calcium overload; HSP70 is 
involved in the cardioprotection obtained by preconditioning and postconditioning 
[160]. HSP70 is upregulated in cardiomyocytes during IRI [161] and this may be 
attributed at least in part, to excessive oxidative stress [162], since the accumulated 
ROS may enhance the activity of heat shock factor 1 and facilitate its translocation into 
the nucleus, which contributes to the induction of HSP70 in ischemia/reperfusion [162]. 
Several studies have suggested that hyperlipidemia can impair the cardioprotective 
effects of HSP70 against IRI. Indeed, HSP70 downregulation was observed in 
cholesterol-fed rats subjected to myocardial ischemia/reperfusion [163], potentially due 
to activation of glycogen synthase kinase (GSK)3  [164]-[165] as well as accumulation 
of cholesterol in the membrane of cardiomyocytes, which might prevent accumulation 
of HSP70 during IRI [163]. 
The hypoxia-inducible factors (HIFs) and downstream genes are important 
factors in the protection of tissues from IRI. Redox signaling during IRI contributes to 
protective or adaptive responses and HIF-1  is one of the first response elements to R  
at the molecular level [166], and plays a pivotal role in the endogenous protective 
mechanism against ischemia [167]. HIF-1  expression was maintained at a very low 
level in hyperlipidemic rats and HIF activation using pharmacological prolyl 
hydroxylase inhibitors results in a level of cardioprotection similar to that obtained with 
ischemic postconditioning [168].  
Nrf2 regulates antioxidant gene expression in vascular cells after exposure to 
modified LDL [169] and oxidized phospholipids in vivo [170]. Nrf2 deficiency in a 
more human-like hypercholesterolemia LDL receptor (LDLR)-KO/ApoB100/100 
female mouse model, promoted plaque inflammation and oxidative stress leading to 
increased plaque instability, which is considered as a risk factor of MI in humans [169]. 
Crocus sativus L. aqueous extract induced cardioprotection in ApoE-KO mice 
undergoing myocardial IRI through activation of Nrf2 and its downstream targets 
SOD2 and heme oxygenase 1, with the subsequent regulation of nitro-oxidative stress 
indicating that the activation of Nrf-2 might be a central mechanism of the 
cardioprotective effect of Crocus sativus L  [171]. 
In summary, hypercholesterolemia results in increased myocardial oxidative 
stress, mainly from NOXs, uncoupled eNOS, mitochondria, XO and 
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downregulation of antioxidant defense systems all of which play important role in 
IRI and may account for increased susceptibility of the myocardium to infarction. 
Increased LDL and oxLDL stimulate the production of ROS and reduce NO 
bioavailability predisposing the endothelial cells of large arteries to an 
inflammatory phenotype. Inflammation is associated with further increased ROS 
production that may overcome cellular defense mechanisms leading to 
atherogenesis, and eventually to loss of contractile function and vascular 
dysfunction [172]. As a result the infarct size is aggravated in a model of high fat 
diet and the protective effects of post-conditioning are lost (Figure 2) [173]. Statins, 
and pharmacological agents that modulate NO bioavailability, possess antioxidant 
properties and interfere with antioxidant defense systems may provide beneficial 
effect in the myocardium in hypercholesterolemic conditions.  
 
4. Diabetes 
According to WHO data, the global prevalence of diabetes mellitus (DM) in 2014 was 
estimated to be 9% [12]. DM increases the risk of MI almost 2-fold (odds ratio 1.89) 
[94]. High fasting blood glucose ranks third among the leading risk factors for 
disability-adjusted life years (years lived with severe illness) based on the global burden 
of disease data for 2019 [13]. Approximately 60% of preclinical studies examining type 
2 diabetes mellitus (T2DM) in in vivo models of regional ischemia/reperfusion, 
demonstrated increased infarct size with T2DM when compared to non-diabetic 
controls; 20% of these studies showed that T2DM was without effect on infarct size 
[174]. However, in these preclinical in vivo models the T2DM animals were almost all 
untreated for the presence of diabetes, causing large differences in plasma glucose 
levels between diabetic and control animals (e.g. blood glucose values of 450-550 
mg/dl in ZDF rats). This contrasts with T2DM in humans, where known diabetes is 
almost always treated by antidiabetic drugs or insulin to normalize plasma glucose 
levels. Therefore, preclinical studies possibly overestimate the effects of T2DM on 
infarct size by allowing these differences in glucose levels. 
Indeed, when only the isolated hearts of T2DM animals were studied, which is 
commonly performed using similar perfusate glucose levels between groups, the 
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proportion of studies reporting a detrimental or neutral effect of T2DM on infarct size 
was equal [174]. Thus, it seems that elevated plasma glucose levels are a main 
determinant of infarct size. This is also in agreement with clinical studies examining 
infarct size during e.g. by-pass surgery or percutaneous coronary interventions (PCI) 
for diabetic and non-diabetic patients. Myocardial infarct size strongly correlated with 
plasma glucose levels and less so with T2DM, with even larger infarct size reported for 
non-diabetic than for diabetic patients presenting with similar glucose levels [175]. 
Thus, whereas it is clear that DM does in general increase CVD by 40-250% in DM 
patients receiving standard of care [176, 177], e.g. for incidence of cardiovascular 
death, HF or MI, the DM effects on sensitivity towards an ischemic event are less 
pronounced and are not always observed; this is also in accordance with the rather 
moderate odds ratio of MI associated with diabetes mentioned above. 
4.1 Diabetes and redox signaling in myocardial infarction 
Increased ischemic sensitivity of the heart is present with DM and can be ascribed to 
elevated plasma glucose and fatty acid levels and disturbed insulin, and/or to numerous 
molecular changes within the diabetic heart. Dysregulated redox signaling emerges 
prominently as one of the important T2DM-induced molecular changes and is mostly 
reflected by increased oxidative stress [178, 179]. Although increased reductive stress 
can also be detrimental to cardiac function [180], the diabetic heart commonly displays 
a depressed reductive stress response, as reflected by a diminished Nrf2-related gene 
response (e.g. depressed antioxidant enzyme complexes) [181]. The reduced reductive 
stress response will contribute to the net increase of oxidative stress within the diabetic 
heart. The cardiac oxidative stress is largely a result of metabolic overload by elevated 
plasma glucose and fatty acid levels. Both acute and chronic plasma glucose and fatty 
acid elevations cause oxidative stress in tissues and organs [182, 183] contributing to 
the increased ischemic sensitivity of diabetic heart [174]. There are many different 
cellular ROS sources in the heart that have been shown to be activated in the diabetic 
state [179, 184]. In addition, hyperglycemia is associated with a low-grade 
inflammatory phenotype, partly triggered by advanced glycation end-product 
(AGE)/receptor of AGE (RAGE) signaling [185, 186]. 
The three major sources in the cytosolic compartment are NOX2, uncoupled 
eNOS and XO in diabetic animals [187]. Other reports have proven that each of these 
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cytosolic ROS components may be activated with diabetes and can contribute to 
ischemia-reperfusion [188-192]. Genetic Nox2 deficiency prevented the major diabetic 
complications in streptozotocin (STZ)-treated mice [193] and insulin resistance-
triggered endothelial cell dysfunction largely relies on NOX2 activity [194]. NOX1-
derived ROS contribute to immune cell activation and vascular infiltration in diabetic 
ApoE-KO mice [195]. In contrast, NOX-4-derived H2O2 seems to be protective in 
diabetic mice [196]. 
The major sources in the mitochondrial compartment entail the ETC, MAO and 
p66Shc [179]. In a seminal report it was demonstrated that high glucose resulted in 
increased ETC-produced ROS in endothelial cells through increases in the 
mitochondrial membrane potential, affecting four different pathological biochemical 
pathways contributing to hyperglycemia-associated oxidative stress and damage [197, 
198]. In these studies, it was suggested that high glucose resulted in increases of 
mitochondrial potential through increased delivery of oxidation-prone substrates and 
reducing factors (NADH, NADPH) to the ETC. Additionally, it is also possible that 
part of the increased mitochondrial potential is due to hyperglycemia-induced 
dislodgement of hexokinase II (HKII) binding to mitochondria [199, 200]. Decreasing 
the amount of mitochondria-bound HKII is known to increase ROS production in the 
heart [200-202], and diabetic hearts have been reported to have less HKII bound to 
mitochondria [203, 204]. Less HKII bound to mitochondria was also recently suggested 
as a possible explanation for increased oxidative stress with aging [205], providing at 
least one explanation for why sensitivity to an ischemic insult may be particularly 
exaggerated in the aging diabetic patients. The cytosolic adaptor protein p66Shc can 
translocate to the mitochondrial matrix upon high glucose-induced PKC activation. 
Once in the mitochondrial matrix the protein catalyzes electrons going from 
cytochrome C directly to oxygen, thereby contributing to H2O2 production [206]. 
Finally, MAOs at the outer mitochondrial membrane breakdown catecholamines and 
neurotransmitters with concomitant generation of H2O2 [207]. Both p66Shc and MAO 
related ROS production can contribute to increased cardiac ischemic sensitivity [42]. 
Genetic deficiency of mitochondrial aldehyde dehydrogenase resulted in increased 
immunohistochemical staining of cardiac 4-hydroxynonenal and diastolic dysfunction 
in diabetic mice [208]. 
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Although many different cellular sources of ROS exist in the diabetic heart, it 
is important to recognize that these sources are not independent entities, because of the 
now well-accepted ROS-induced ROS production [209, 210], which is also well 
documented in the setting of diabetes [186]. Thus, although ROS production could start 
with one source, this can quickly result in the activation of other ROS sources, making 
it difficult to discern the primary cause of ROS production. ROS can contribute to 
cardiac infarct development by facilitating the opening of the mPTP during early 
reperfusion, resulting in mitochondrial dysfunction and activating necrotic pathways 
[211]. In addition, mitochondrial dysfunction and ROS generation will activate the 
innate immune receptor nucleotide-binding oligomerization domain, leucine rich repeat 
and pyrin domain containing NLRP 3, an immune receptor whose presence is already 
increased in diabetes, thereby contributing to cardiac infarct development through 
pyroptosis [212]. Finally, ROS can also induce the endoplasmic reticulum stress 
response, thereby contributing to infarct size through necroptosis [53, 213]. 
4.2 Pharmacological redox modulation in diabetes and cardioprotection 
As discussed above, an excess of ROS induced by hyperglycemia contributes to the 
enhanced basal oxidative stress and is likely to aggravate myocardial IRI in diabetic 
patients. As such, therapeutic interventions to decrease oxidative stress could, in 
principle, protect against hyperglycemia-induced myocardial tissue damage. However, 
although increasing evidence favors protection by antioxidants and ROS scavengers, 
the potential of reducing oxidative stress to treat the diabetic heart is still controversial 
and equivocal in human studies. Antioxidants such as ascorbic acid and N-
acetylcysteine prevent NOS uncoupling in the diabetic heart resulting in increased 
bioavailability of NO and increased tolerance to IRI in diabetic rat heart [214].   
Diabetic heart mitochondria demonstrate an enhanced susceptibility to injury, 
mediated by redox-dependent shifts in mPTP opening [215]. In this context, diabetic 
mice treated with a mitochondria-targeted antioxidant (MitoTEMPO) displayed 
preserved heart rates and better survival after MI by suppression of calmodulin-
dependent protein kinase-II (CAMK-II) oxidation [216] and mitochondrial ROS/RNS 
generation, apoptosis and myocardial hypertrophy [217]. The latter observations were 
also confirmed ex vivo in cultured cardiomyocytes subjected to hyperglycemia. 
Compounds other than direct antioxidants, that attenuate mPTP opening, such as a 
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newly developed cyclophilin D inhibitor (NIM811), were reported to reduce infarct size 
when administrated at reperfusion in STZ diabetic rats [218].Pharmacological 
inhibition of histone deacetylase 6, which confers redox regulation and suppresses 
cellular stress responses, showed highly beneficial effects in STZ-induced and 
ischemia/reperfusion-subjected diabetic hearts, potentially based on modulation of 
acetylation of peroxiredoxin 1 (Prdx1) and thereby decreasing ROS levels [219]. As 
another mitochondria-targeted approach, inhibition of MAO attenuated diabetic 
cardiomyopathy [53, 179]. 
Stabilization of HIF-1  has been reported to promote tolerance against acute 
myocardial IRI by decreasing mitochondrial oxidative stress and inhibiting mPTP 
opening [220], while the HIF-1 signaling pathway is compromised in the diabetic 
setting [221]. When diabetic rats were treated with N-acetylcysteine or the XO inhibitor 
allopurinol, HIF-1 /heme oxygenase-1-dependent signaling was stabilized and 
consequently myocardial IRI was attenuated [222]. Further studies have revealed that 
cobalt (II) chloride (CoCl2) can activate the impaired HIF-1  pathway under diabetic 
conditions [223]. CoCl2 or deferoxamime-activated HIF-1  signaling pathway restored 
the sevoflurane postconditioning-dependent myocardial protection in diabetic rats by 
improving myocardial mitochondrial respiratory function and mitophagy and reducing 
ROS generation [224-226]. 
Phosphodiesterase-5 (PDE5) inhibitors have been described to protect the heart 
against IRI through several mechanisms involved in increased expression of NOS, 
activation of protein kinase G (PKG)-dependent hydrogen sulfide (H2S) generation, and 
phosphorylation of GSK-3   which modulates mPTP directly [227]. PDE5 inhibition 
improves endothelial function and promotes antioxidant activity in the diabetic heart 
through increasing NO bioavailability [228]. In this context, tadalafil therapy attenuates 
oxidative stress and improves mitochondrial integrity while reduces myocardial infarct 
size following IRI in db/db mice [229]. 
Melatonin, a cellular antioxidant and direct ROS scavenger, exerts protection 
against myocardial IRI in T2DM rats by limiting reperfusion-induced ROS formation 
and endoplasmic reticulum stress in a SIRT1-dependent manner [230]. In acute 
hyperglycemia, melatonin rescued the thioredoxin (Trx) system in the heart by reducing 
Trx-interacting protein expression via neurogenic locus notch homolog protein 
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(Notch)1/ enhancer of split 1 (Hes1)/ Akt signaling [230, 231]. Furthermore, melatonin 
prevented myocardial IRI in STZ-induced diabetic rats by normalizing mitochondrial 
function and oxidative stress as well as stimulation of mitochondrial biogenesis via 
AMPK-PGC1 -SIRT3 signaling [232]. 
Resveratrol has been shown to have pleiotropic and beneficial effects on 
cardiovascular complications in DM, including amelioration of mitochondrial function 
and oxidative stress as well as amelioration of endothelial function mainly through 
mechanisms involving NO and SIRT pathways [233-236]. In addition, pterostilbene, a 
naturally-occurring dimethylated analogue of resveratrol with antidiabetic effects, 
significantly reduced post-ischemic cardiac infarct size, oxidative stress, and apoptosis 
in diabetic rats. Pterostilbene enhanced the viability of cardiomyocytes exposed to 
hypoxia-reoxygenation under high glucose conditions and decreased ROS formation 
[237]. Other bioflavonoids (e.g. quercetin, rutin or benzenetriol), also displayed 
cardioprotective effects in IRI in diabetic rats, which partially rely on the attenuation of 
oxidative stress and improvement of antioxidant reserves [238, 239]. On the other hand, 
quercetin was not effective in preventing myocardial IRI in ZDF rats implying that 
other confounding factors may abolish the cardioprotective effect [240]. 
Other polyphenolic compounds such as luteolin, butin, and berberine may 
inhibit oxidative stress and protect against IRI in diabetic mice via eNOS/ Kelch-like 
ECH-associated protein (Keap1)/Nrf2 or AMPK/Akt/GSK-3 /Nrf2 dependent 
pathways [241-244]. (-)-Epigallocatechin-3-gallate, a green tea polyphenol with potent 
antioxidant properties, decreased myocardial infarct size and apoptosis as well as 
oxidative stress via SIRT1-dependent pathways in STZ-diabetic rats with myocardial 
IRI [245]. Furthermore, attenuation of myocardial IRI in diabetic rats was observed by 
the dietary flavonoid kaempferol by suppression of AGE-RAGE/mitogen activated 
protein kinase (MAPK)-dependent inflammation and oxidative stress [246].  
Increasing evidence documents the beneficial effects of SLGT2 inhibitors in the 
heart, directly or indirectly, in animal and human studies, including decreasing 
oxidative stress and preventing IRI [247, 248]. Long term, but not short term, SGLT2 
inhibition by empagliflozin, attenuated myocardial IRI in vivo in diabetic and non-
diabetic mice through regulation of oxidative stress [85, 249]. Treatment with 
empagliflozin significantly attenuated the DM-induced increase in acute mortality after 
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MI in a model of T2DM through preservation of myocardial antioxidant defense and 
normalization of the size and number of mitochondria [247, 250, 251]. Studies on the 
effects of a diverse range of antioxidants on cardiac effects in cardiometabolic 
comorbidities are presented in Table 1.  
In conclusion, the diabetic comorbidity is associated in general with 
exacerbated ROS generation within the heart, originating from both cytosolic and 
mitochondrial sources, and most often driven by metabolic overload of glucose 
and fatty acids as well as an inflammatory phenotype. Increased oxidative stress 
s or increases the 
sensitivity of the heart to ischemia, which, at least in preclinical studies, can be 
prevented by antioxidant strategies. As a result of this impaired redox balance, 
infarct size is aggravated in a model of diabetes and further exacerbated by genetic 
heme oxygenase-1 deficiency (Figure 2) [252]. Strategies to combat this oxidative 
stress therefore seem warranted. 
 
5. Hypertension/hypertrophy 
According to WHO data, the global prevalence of hypertension was estimated to be 
approximately 30% in the adult population [253]. Hypertension increases the risk of 
MI almost 3-fold (odds ratio 3.11) [94] and ranks first among the leading risk factors 
for disability-adjusted life years (years lived with severe illness) based on the global 
burden of disease data of the year 2019 [13].
be applied broadly to describe the composite result of the morphological, metabolic, 
microvascular and electrophysiological perturbations that predispose to greater CVD 
risk in patients with hypertension. A key feature of hypertensive heart disease is 
concentric left ventricular hypertrophy (LVH) [254]. Increased left ventricular muscle 
mass initially helps to pump more efficiently against an increased ventricular afterload. 
Estimates vary but more than 20% of hypertensive patients may develop 
echocardiographic evidence of LVH [255-257] and it is well established that 
hypertensive patients with LVH have a worse prognosis than those without detectable 
LVH. While hypertension is a major risk factor for the development of IHD, 
hypertensive LVH presents an additive risk for all forms of cardiac rhythm 
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disturbances, sudden cardiac death, HF and, most pertinent in the context of the current 
review, atherothrombotic events including MI [258-260]. 
 
5.1 Hypertension/LVH and redox signaling in myocardial infarction  
Widespread disturbance of cellular redox balance throughout the circulatory system is 
recognized as a general feature of arterial hypertension, whether of primary or 
secondary etiology. In experimental models of hypertension or other forms of pressure 
overload, LVH is accompanied by many biochemical, metabolic and signaling 
disturbances that have been associated with cardiomyocyte hypertrophy, altered 
myofibrillar contractility, interstitial fibrosis and gradual progression to 
decompensation and HF. Many studies show that increased ROS-generating capacity, 
reduced endogenous anti-oxidant defense and impaired NO generation are general 
features of hypertrophic myocardium and are related to altered sensitivity of 
hypertrophied tissue to stressful stimuli such as ischemia-reperfusion [261-264]. 
The major sources of ROS in cardiomyocytes and the key antioxidant systems 
have been reviewed extensively before [265, 266]. Redox signaling is a critical factor 
in physiological myocyte hypertrophy in post-natal growth and in response to stressful 
stimuli. In arterial hypertension, the progression from a state of adaptive cardiac 
hypertrophy to a maladaptive state, when myocyte contractility is impaired and HF 
develops, is clearly associated with oxidative stress. The nature and causes of the 
imbalance between ROS generation and antioxidant defense mechanisms in 
hypertension are unclear although they are likely to be complex, multifactorial and 
dependent on the etiology of hypertension in humans or the nature of the experimental 
model in in vivo and in vitro models.  
Many of the kinase cascades and their target proteins that regulate transcription, 
protein synthesis and myocyte growth, for example members of the MAPK family 
extracellular signal-regulated kinases (ERK)1/2, Akt, GSK3  and the nuclear factor of 
activated T-cells (NFAT) family of transcription factors, are ROS-activated or redox-
sensitive [267-270]. In evolving or compensated hypertrophy, ROS may be from 
mitochondrial or non-mitochondrial sources. The major neurohormonal mediators of 
myocyte hypertrophy in hypertension, namely catecholamines and angiotensin II, 
stimulate hypertrophy in vivo or in vitro through mitochondrial ROS generation via the 
ETC complexes [271-273]. MAO-associated ROS generation may also contribute 
beyond ROS generated by the ETC complexes. MAO-A and MAO-B activities were 
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shown to be enhanced in cardiomyocytes from spontaneously hypertensive rats at a 
stage before detectable hypertrophy was established [274-276] [277]. However, 
cytosolic (non-mitochondrial) ROS-generating enzymes also appear to play important 
roles in physiological myocyte hypertrophy. These include XO [266]. In Dahl salt-
sensitive rats, high salt diet increased myocardial XO activity, was accompanied by 
increases in blood pressure, LV mass index and interstitial fibrosis during the initial 8-
week period of hypertension and LVH development. Febuxostat, a selective XO 
inhibitor attenuated these increases as well as markers of oxidative stress, suggesting 
that in this model of hypertension, XO-derived ROS are mediators of cardiomyocyte 
hypertrophy and interstitial fibrosis [278].  
Evolving experimental evidence suggests that other non-mitochondrial sources 
of ROS may be relevant to both physiological cardiac hypertrophy and pathological 
decompensation leading to HF. Most prominent are the NOX isoforms of non-
phagocytic origin of which NOX2 and NOX4 have received most attention [279-282]. 
Calcium/calmodulin-dependent NOX5 may also be implicated [283]. The extent to 
which these various pathways of ROS production are co-regulated or exhibit cross-talk 
is unclear. However, it is of interest that selective XO inhibition in the Dahl salt-
sensitive rat also reduced total NOX activity [278] and the angiotensin II type 1 receptor 
antagonist, candesartan, decreased both XO and NOX activities in parallel [284].  
Progression of LVH from an adapted (compensated) state to decompensation 
and HF appears to be associated with multiple biochemical and metabolic alterations 
that shift redox balance towards a state of oxidant stress. Although the functional 
decline is often difficult to define clinically and even more difficult to model 
experimentally, many studies show that enhanced oxidant stress is a feature of the 
progression. Alterations in substrate metabolism [285] and the ETC complexes [286], 
increased expression and activity of MAO [275, 287-290], upregulation of XO [261] 
and increased activity of NOX isoforms [291] have been implicated in mediating 
excessive ROS production associated with LVH progression and decompensation.  
There is also evidence that many endogenous antioxidant systems are depleted 
or become inactivated during the progression of LVH, either as a cause or a 
consequence of decompensation. For example, reduced total (cytosolic and 
mitochondrial) SOD activity [261] is a feature even in the compensated state and 
accompanied by reduction in the ratio of reduced glutathione (GSH)/oxidized 
glutathione (GSSG) [292] in the transition to HF. Trx1 inhibits cardiac hypertrophy 
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through a number of redox-controlled downstream mechanisms [293]. Depletion or 
inhibition of Trx increases hypertrophy and may predispose to decompensation. A 
growing body of evidence suggests that the gaseous thiol H2S, generated through 
regulated enzymatic pathways in myocardium and the coronary vasculature, may also 
represent an important antioxidant in myocardium although the mechanisms are as yet 
unclear. While direct chemical interaction and scavenging of ROS would seem to be a 
simple mechanism, evidence is emerging of more complex redox regulation by H2S, 
especially in the mitochondria (reviewed in [294]). Recent evidence indicates that 
deletion of the most abundant H2S-generating enzyme in the heart, 3-mercaptopyruvate 
sulfurtransferase (3-MST), had no effects on blood pressure or LV mass in young 
animals but was associated with hypertension and LVH in aged mice [295]. There is 
limited evidence of mechanisms by which H2S might modify physiological and 
pathological processes in hypertrophy. SIRT3 is a mitochondrial histone deacetylase 
controlling protein deacetylation and thereby influences substrate metabolism and 
mitochondrial redox status. In human LV tissue, SIRT3 expression correlated inversely 
with the severity of pathological changes [296]. In experimental LVH, elevation of H2S 
availability through exogenous administration increased the expression of SIRT-3, 
improved several measures of mitochondrial function and attenuated the hypertrophic 
response to pressure overload in a SIRT3-dependent manner [297].  
Enhanced oxidative stress through increased ROS generation and/or depletion of 
intracellular antioxidant systems may predispose the hypertrophied myocardium to 
altered responses to acute ischemia/reperfusion and modify the response to protective 
interventions, notably preconditioning and postconditioning treatments. Responses to 
ischemia/reperfusion in experimental LVH have been comprehensively reviewed 
elsewhere [11, 156]. Briefly, many experimental studies confirm that the severity of 
arrhythmias during both coronary occlusion and reperfusion is increased in 
compensated LVH, mirroring extensive clinical observations of enhanced susceptibility 
to malignant arrhythmias and sudden death in patients with LVH. There is also 
experimental evidence that myocardial stunning (delayed recovery of contractile 
function during reperfusion following ischemia) is exaggerated in LVH [261, 263, 298]. 
Augmented irreversible tissue injury, measured as infarct size, has been observed in 
short-term experimental models of myocardial infarction in hypertensive LVH [299-
301] although not consistently [302, 303]. However, it is conceivable that long-term 
responses to MI could be modified in LVH due to the combination of decreased 
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microvascular density, interstitial/perivascular fibrosis and persistent oxidant stress. 
Although experimental evidence is lacking, one could predict an exaggerated post-
infarct inflammatory response in the hypertrophied heart leading to less favorable tissue 
remodeling and worse outcome [304]. 
5.2 Pharmacological redox modulation in hypertension/hypertrophy and 
cardioprotection 
Protection of the hypertrophied myocardium from the consequences of 
ischemia/reperfusion has arguably received less attention than it deserves. Long-term 
treatment with antihypertensive drugs can lead to regression of LVH. Although blood 
pressure lowering and control of LV afterload is clearly an important goal, some 
antihypertensive drug classes are associated with better LVH regression and their 
effects on LV mass go beyond blood pressure control. For example, angiotensin 
converting enzyme inhibitors, -adrenoceptor antagonists and L-type calcium channel 
blockers induce LVH regression which is not observed with thiazide diuretics or older 
vasodilators such as hydralazine and minoxidil. However, it remains unclear if LVH 
regression induced by antihypertensive drug therapy is truly associated with reduced 
risk of major events and improved prognosis [305, 306]. Given this uncertainty, 
cardioprotection of the hypertrophied myocardium against ischemia-reperfusion injury 
remains an important therapeutic goal.  
Several studies suggest that the endogenous cardioprotective mechanism, 
ischemic preconditioning, is applicable and effective in young animals with 
experimental LVH, at least during the early stage of hemodynamic compensation [302, 
303, 307-311]. However, in long-standing or progressive LVH, even without evidence 
of decompensation, preconditioning protection (ischemic or pharmacological) may be 
attenuated or require a higher intensity preconditioning stimulus to be effective 
compared to age-matched control animals [312, 313]. Observations of postconditioning 
in hypertrophied myocardium are limited but the bulk of evidence to date suggests that 
the postconditioning mechanism is abrogated even in young animals with short-term 
hypertension [314-317].  
Excessive ROS accumulation, particularly from mitochondrial sources, is 
known to trigger mPTP opening during early reperfusion [318] and it has been 
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suggested that the greater susceptibility of hypertrophied myocardium to IRI is, at least 
in part, related to enhanced opening of mPTP [301, 319]. There is some evidence that 
oxidative stress and the impairment of mitochondrial homeostasis and redox signaling 
mechanisms that is seen in advanced or decompensated LVH may be related to 
attenuation of the preconditioning response. For example, isoflurane preconditioning 
increased SOD2 activity in normotensive rats and limited infarct size but these 
responses were lost in hypertensive animals with established LVH [299]. Fantinelli and 
colleagues [320] have demonstrated a change in ischemic preconditioning threshold 
required to confer protection in hypertrophied hearts but protection was associated with 
preservation of GSH (an indicator of reduced oxidant stress) and decreased cytosolic 
accumulation of SOD2 (a surrogate indicator of mPTP opening).  
Although there is clear evidence that oxidant stress is a mediator of pathological 
hypertrophy development/decompensation and of enhanced IRI in LVH models, the 
potential of exogenous antioxidants as clinical cardioprotective agents has so far met 
with limited success. Key issues, common to many experimental ischemia-reperfusion 
studies, have been the right antioxidant, in the appropriate biological compartment 
(extracellular/cytosolic/mitochondrial), at the right concentration, at the right time. The 
experimental literature is extensive and extends over several decades. It includes 
antioxidant enzymes (CAT, SOD); inhibitors of ROS-generating enzymes (e.g. 
allopurinol); phytochemical ROS-scavenging agents such as purified derivatives or 
galenical plant extracts containing polyphenolic secondary metabolites (e.g. flavonoids 
such as quercetin, curcuminoids, anthocyanins and stilbenoids like resveratrol); 
vitamins, notably ascorbate/vitamin C and tocopherol derivatives/vitamin E; and 
synthetic agents such as N-acetylcysteine and 4-hydoxy-TEMPO (Tempol). Some of 
these agents have been applied as tools for investigation of the role of oxidant stress 
both in the mediation of experimental hypertrophy and ischemia-reperfusion injury (see 
Table 2). It is important to note that action may not be specific and the difficulties of 
dose standardization, particularly in the case of the complex phytochemical 
preparations.  
Despite clear evidence of oxidative stress in the pathophysiology of 
hypertensive LVH and ischemia/reperfusion injury, and promising beneficial effects in 
some laboratory models, no antioxidants so far have been established in large 
randomized control trials to exert benefit in hypertension, either through attenuation of 
hypertrophy progression towards decompensation/HF, or cardioprotection against 
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ischemia/reperfusion injury (see [321] for extensive review). Smaller clinical studies 
that have investigated allopurinol as adjunct to standard treatment for hypertension or 
heart failure have shown marginal benefit or even a detrimental effect [322, 323].  
The reasons for this divergence between experimental and clinical experience 
are likely to be wide-ranging. Reasons may include the vast number of biological 
targets for antioxidant action some of which may be essential redox pathways 
controlling normal homeostasis; the huge diversity of chemical structure and 
mechanisms of action of antioxidants; lack of specificity of antioxidant compounds; 
and the complexities of multiple-morbidity and co-existing drug treatments (some of 
which may have inherent antioxidant activity [324, 325]. These difficulties render the 
demonstration of antioxidant benefits in human hypertension a challenging and high-
risk endeavor.  
In conclusion, redox signaling is a critical molecular mechanism controlling 
cardiomyocyte hypertrophy in pressure overload conditions like hypertension.  
Although LVH is initially an essential adaptive phenomenon that maintains 
cardiac output in the face of increased afterload, chronic pressure overload and 
neurohormonal influences contribute to increasing oxidative stress, characterized 
by excessive ROS production and reduced antioxidant capacity. These factors 
predispose the hypertrophied myocardium to exaggerated IRI and development 
of HF. Under experimental conditions, in vivo and in vitro, a wide variety of 
antioxidants have been shown to modify the hypertrophic response to pressure 
overload or pro-hypertrophic neurohormonal stimuli and mitigate against the 
deterioration to HF. However, clinical application of antioxidant approaches for 
hypertensive heart disease has so far been limited in scope and requires further 
exploration as a possible approach to management of this insidious condition. 
 
6. Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic 
steatohepatitis (NASH) 
 NAFLD accounts for an appreciable part of chronic liver disease with a prevalence of 
~30% of the US population [326]. Approximately 10-15% of the patients with NAFLD 
develop NASH , which is characterized by hepatic apoptosis, inflammation, steatosis, 
and fibrosis, with a substantially higher risk of cirrhosis and primary liver cancer [327]. 
Of note, there is a clear association of cardiovascular risk and mortality with the severity 
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of NASH [328], as supported by increased carotid intima-media thickness as well as 
aggravated coronary calcification and endothelial dysfunction in patients with NASH 
[328, 329]. NASH increases the risk of MI by 50% (odds ratio 1.5) [94] and fatty liver 
disease also contributes significantly to the global burden of disease in terms of 
disability-adjusted life years [330]. Previous reports provided indirect proof for a role 
of oxidative stress in hepatic endothelial dysfunction [331], which was also supported 
by improved hepatic endothelial function upon infusion of high dose vitamin C in 
patients with liver cirrhosis [332]. NAFLD is connected with DM, which represents 
another metabolic disease with a clear association with oxidative stress and higher 
cardiovascular risk [333, 334], thereby supporting the notion of liver disease as a 
cardiovascular comorbidity [335]. 
So far, there are only a limited number of studies that have investigated the 
correlation of liver damage progression with oxidative stress or cardiovascular risk. 
Studies that explored the benefit of combined pharmacological targeting of liver and 
cardiovascular inflammation are rare. Whereas macrophages, freshly recruited or 
resident ones, may represent a common pathophysiological feature, their detailed role 
in NASH as well as their pharmacological modulation remain insufficiently studied 
[336, 337]. In line with this notion, hepatic levels of TNF- , interleukin (IL)-6, IL-1 , 
and cyclooxygenase-2 were found to be increased in NASH animal models [338-340]. 
As a consequence, hepatic ROS levels are higher in NASH and have been  proposed 
for therapeutic targeting [341]. Therefore, inflammation provides a clear link between 
NAFLD/NASH and CVD  since the progression of atherosclerosis in humans [342, 
343] and arterial hypertension in animals [344, 345] is largely dependent on the 
recruitment and activation of immune cells. The inflammation-triggered oxidative 
stress impairs endothelial function and represents a prognostic marker for higher 
cardiovascular risk [346, 347] and, vice versa, oxidative stress can activate 
inflammatory pathways by different mechanisms leading to a vicious cycle [348, 349]. 
In conclusion, NASH represents an inflammatory liver disease with important 
features of atherosclerosis [350]. Macrophages and dendritic cells derived from blood 
monocytes as well as liver resident macrophages/Kupffer cells drive local immune 
responses in NASH [351] leading to higher levels of hepatic and cardiovascular ROS 
[341, 352]. In analogy to NASH, these cells also play an essential role for the 
progression of atherosclerosis [342, 343] and arterial hypertension [344, 353]. 
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Therefore, CVD may significantly contribute to overall mortality in patients with 
NAFLD/NASH [329]. 
 
6.1 NAFLD/NASH and Redox Signaling in Myocardial infarction  
Oxidative stress has adverse effects on endothelial function and CVD prognosis 
[346]. Oxidative stress plays a central role for NASH and NAFLD disease progression 
(including cardiovascular complications) [354, 355] and NOX-derived ROS represent 
key players in liver fibrosis [356]. Patients with NASH have higher levels of 8-
isoprostanes and sNox2-dp correlating with the histological grading of steatosis as well 
as liver inflammation, ballooning and fibrosis [357]. Patients with NAFLD displayed 
higher sNox2-dp and 8-isoprostane levels that correlated with higher steatosis and 
portal inflammation  [358] or with markers of infection [359]. NOX1 isoform was 
found to be upregulated in livers of NASH patients [360]. As shown by animal studies, 
genetic Nox1 or Nox2 deficiency attenuated the major biochemical and functional 
markers of NASH in high fat diet fed mice [360, 361]. A cell culture study demonstrated 
that advanced glycation end products may play a role for inflammatory activation of 
hepatic stellate cells by a NOX2-dependent pathway [362].  
Apart from NOX isoforms, mitochondrial ROS formation has been identified as a 
major source of oxidative stress in the setting of NAFLD/NASH, which is a 
consequence of altered mitochondrial morphology and function as well as inhibition of 
the ETC [363-365]. Enhanced p66shc signaling, increased opening probability of the 
mPTP and higher levels of mitochondrial damage-associated molecular patterns 
(DAMPs) were reported for rodent models of NASH [366-368] that may explain the 
increased mitochondrial ROS formation. XO inhibition could efficiently prevent the 
major pathophysiological changes in rodent models of NASH [369, 370]. Finally, 
neuroinflammatory processes through the liver-brain-axis may come into play, again 
involving ROS formation (e.g. via NOX2) [371], which may affect neuronal stress 
hormone signaling and thereby affect cardiovascular function [372]. Of note, the above-
mentioned ROS sources can activate each other in a crosstalk fashion and are 
recognized mediators of ischemia/reperfusion damage during myocardial infarction 
[373, 374]. 
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Endothelial function measured by FMD, a prognostic parameter was reduced and 
carotid artery intima-media thickness was increased, indicating higher CVD risk in 
patients with NAFLD or NASH [375, 376]. Importantly, sNox2-dp and isoprostane 
levels in patients with NASH also correlated with peripheral endothelial dysfunction 
measured by FMD, all of which was corrected by administration of polyphenol-rich 
dark chocolate [377]. These data were in line with observations in a NASH model 
(methionine/choline-deficient diet) linking liver steatosis, inflammation, fibrosis and 
oxidative stress with an adverse vascular phenotype characterized by endothelial 
dysfunction, ROS formation from mitochondria, NOX1 and NOX2 as well as vascular 
inflammation in peripheral vessels [352]. Taken together, these data support and 
explain the higher risk of MI associated with NASH [94] and the higher CVD risk of 
patients with NAFLD [378, 379]. 
 
6.2 Pharmacological redox modulation in NAFLD/NASH and 
cardioprotection 
Therapy with vitamin E and PPAR  agonists (e.g. pioglitazone) was recommended 
as combination therapy for NASH patients and confers potent antioxidant and anti-
inflammatory protection; this  provides further support for oxidative stress as a central 
pathophysiological mechanism in NASH [335]. These lines of evidence are supported 
by meta-analysis showing that vitamin E supplementation improves major disease 
parameters in NAFLD patients, endorsing the oxidative stress concept in fatty liver 
disease [380]. The synthetic ROS scavenger mito-TEMPO prevented NAFLD 
associated liver inflammation and steatosis [381] and the related compound mitoQ will 
most likely show similar beneficial effects [382]. The natural antioxidant flavonoid 
silibinin improved adverse effects of NASH on the liver and heart in a mouse model 
(methionine/choline-deficient diet) [383]. Similarly, resveratrol ameliorated all adverse 
features of NAFLD [384]. Treatment of NASH mice with nanoformulated SOD1 
prevented the NASH phenotype [385]. Pharmacological activation of retinoic acid-
with an improved NASH phenotype in mice [386]. Vice versa, genetic deletion of 
SOD1 and the senescence marker protein-30 was associated with oxidative stress and 
hepatic steatosis [387]. 
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Animal studies demonstrated a beneficial effect of incretin-based therapies 
(glucagon-like peptide-1 [GLP-1] mimetics and dipeptidyl peptidase-4 [DPP-4] 
inhibitors) on the vascular system, including inhibition of atherosclerosis, myocardial 
and kidney fibrosis [388-391]. A limited number of studies using NAFLD and NASH 
models demonstrated anti-inflammatory and antioxidant effects [392-394], although 
these studies focused mainly on aspects of hepatocyte damage and steatosis. Also, 
synergistic effects of GLP-1 administration on liver inflammation and systemic 
atherosclerosis were reported [395]. Effects of DPP-4 inhibitor (gliptin) therapy on 
NAFLD/NASH associated oxidative and inflammatory complications in the liver and 
vascular tissue were demonstrated using a NASH mouse model (methionine/choline-
deficient diet) [352]. Gliptins increased GLP-1 levels and thereby suppressed NOX and 
mitochondria-derived ROS formation and markers of inflammation in the aorta. This 
may be explained by GLP-1-dependent inhibition of PKC and NF B-mediated NOX 
activation and upregulation [396, 397]. Alternatively, higher GLP-1 levels may 
contribute to AMPK activation that controls macrophage polarization and antioxidant 
defense [350, 391]. The indirect antioxidant effects of incretin-based therapies are 
further supported by reports of reduced oxidative stress markers in models of DM [396-
399], atherosclerosis [388, 400], sepsis [389, 391], cardiac IRI [401] and chronic MI. 
 Another novel antidiabetic drug class, SGLT2 inhibitors, are currently under 
consideration for the therapy of NAFLD/NASH [402]. Empagliflozin improved 
markers of liver fibrosis and steatosis in NAFLD patients with and without T2DM [403, 
404]. The drug also ameliorates the phenotype of NASH (fibrosis and steatosis) in mice 
[405]. Importantly, empagliflozin was shown to possess highly beneficial 
cardioprotective effects by decreasing the cardiovascular mortality in larger scale 
studies in T2DM patients [406], which was mechanistically supported by potent 
antioxidant and anti-inflammatory effects of the drug in rodent models of type 1 and 
type 2 DM [334, 407]. These mechanistic considerations on the cardio-metabolic-renal 
benefits of SGLT2 inhibition have been reviewed in detail [408]. 
In conclusion, NAFLD and NASH are associated with a higher burden of 
oxidative stress within the liver and heart, based on activation of cytosolic and 
mitochondrial sources. NAFLD and NASH share similarities in their 
pathomechanisms with DM and the metabolic syndrome, including dysregulated 
lipid metabolism and an inflammatory phenotype (in part also mild 
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hyperglycemia) as well as progression of atherosclerosis. These adverse features 
of NAFLD and NASH explain the aggravated susceptibility to 
ischemia/reperfusion injury of the heart and higher risk of MI for patients with 
NAFLD and NASH. As oxidative stress plays a central role in NAFLD and NASH 
pathophysiology and disease progression as well as associated ischemic heart 
disease, several antioxidant treatment regimens were reported to display highly 
beneficial therapeutic effects in preclinical models of or patients with NAFLD and 
NASH.
7. Conclusions/Future Perspectives 
In order to provide an impression of the increase in CVD risk by the different 
comorbidities discussed above, we summarize the odds ratios for the association of 
each of them with MI using data from a large scale population-based national study 
(55,099,280 patients) [94]. Hyperlipidemia showed the strongest association with MI 
with an odds ratio of 8.39 (95% CI: 8.21-8.58), followed by hypertension with an odds 
ratio of 3.11 (95% CI: 3.05-3.17). DM and NASH showed a comparable odds ratio of 
1.89 (95%CI: 1.86-1.91) and 1.5 [95% CI: 1.40-1.62], respectively. Association of 
other risk factors with MI were smoking with an odds ratio of 2.83 (95% CI: 2.79-2.87), 
age above 65 years with an odds ratio of 1.47 (95% CI: 1.45-1.49) and male gender 
with an odds ratio of 1.53 (95% CI: 1.51-1.55). 
The nature, source, location and rate of production of ROS generated in 
myocardium under physiological or pathological conditions, together with the 
availability of cellular antioxidant defense systems, will determine the balance between 
redox signaling (physiological) and oxidative stress (pathological). The primary major 
sources of ROS in ischemia/reperfusion damage (e.g. during MI) are the mitochondria 
and NOXs, whereas secondary sources are XO and uncoupled NOS [374]. The 
contribution of NOXs was supported by protective effects of the inhibitor apocynin 
[409], which also displayed protection in all discussed comorbidities. Mitochondrial 
ROS play a dual role and can be detrimental but also protective as blockade of the 
mitochondrial ATP-sensitive potassium channel by glibenclamide or 5-
hydroxydecanoate increased infarct size and prevented the protective effects of 
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ischemic preconditioning [410, 411]. Also the inhibition of PKC can induce adverse or 
protective effects by suppression of preconditioning [412], whereas the PKC inhibitors 
chelerythrine or calphostin C conferred protection against most of the discussed 
comorbidities at the preclinical level or in isolated blood cells and platelets of patients. 
Previously, the concept of redox crosstalk between different sources of ROS 
was proposed [413-416], which may help to explain the impact of the above described 
comorbidity factors on MI or cardiovascular death (Figure 3). Based on this concept, 
comorbidities such as arterial hypertension, DM, hypercholesterolemia or 
NAFLD/NASH would activate primary ROS sources such as NOX (e.g. via the renin-
angiotensin-aldosterone or AGE). These ROS from primary sources may increase 
ischemia/reperfusion damage by aggravating mitochondrial ROS formation in a bonfire 
fashion, which will ultimately lead to potentiation of mitochondrial dysfunction 
(impaired ATP-based energy supply), mitochondrial DNA damage, cell death by 
apoptosis and necrosis. The amplification of mitochondrial ROS release will lead to 
damage of vascular signaling and activation of secondary ROS sources such as 
uncoupled eNOS. Aggravated inflammation by ROS-triggered pathways (e.g. redox 
activation of the NLRP3 inflammasome or the central hub of inflammation, HMGB1) 
as well as the increase in circulating levels of DAMPs may further contribute to 
comorbidity-induced ischemia/reperfusion injury [417].  
Oxidative stress is an attractive target for novel therapies, as it represents the 
common pathway through which different CVD comorbidities exert their deleterious 
cardiovascular effects. Although sources such as NOX are common for all the 
comorbidities, other redox signaling alterations may be specific for each comorbidity. 
Therefore, there is an urgent need to better understand the biology of such comorbidities 
and their consequences on the redox system as well as subsequent events such as 
ischemia/reperfusion injury. More mechanistic studies are necessary to characterize the 
sequences of events and to potentially recognize components that may specifically be 
pharmacologically targeted by available drugs or by novel molecules. Figure 3 presents 
novel/unexplored (mostly preclinical) redox therapeutic approaches to interfere with 
these comorbidity-induced adverse redox signaling pathways. 
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Figure 1. Proposed concept of comorbidities in myocardial infarction (MI) with 
oxidative stress and inflammation as central pathomechanisms. (A) Comorbidities 
aggravate adverse health outcomes of MI. (B) Overall burden of the major 
comorbidities in ST-segment elevation and non-ST-segment elevation MI (STEMI and 
NSTEMI) by a population-based study in Beijing (77,943 patients). Adapted from 
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Figure 2. Experimental myocardial infarction in models of diabetes and 
hyperlipidemia (high fat diet). (A) All groups underwent induction of MI (I/R). 
Infarct size was aggravated by hyperlipidemia in high fat diet fed mice. The 
cardioprotective effects of post-conditioning (PostC) were abolished in the high fat diet 
group. The white color in the stainings shows infarcted, necrotic tissue. Reused from 
[173] with permission. Copyright © 2018, Springer Science Business Media, LLC, part 
of Springer Nature. (B) All groups underwent induction of MI. Infarct size was 
aggravated by diabetes in STZ-treated mice. Genetic heme oxygenase-1 deficiency 
further exacerbated the ischemic heart damage. The white color in the stainings shows 
infarcted, necrotic tissue. Reused from [252] with permission. Copyright © 2005, 
American Diabetes Association. 
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Figure 3. Proposed mechanism of the redox crosstalk between different ROS 
sources explaining the aggravation of ischemia/reperfusion damage by 
comorbidity factors. The green and brown boxes represent novel/unexplored genetic 
or pharmacological redox approaches to interfere with the vicious cycle between 
comorbidities and IRI (as observed during MI). Abbreviations: AT1R, angiotensin-II 
receptor (type 1); cy, cytosolic; CsA, cyclosporine A; CypD, cyclophilin D; DAG, 
diacylglycerol; gp91phox, NOX2; MnSOD, manganese superoxide dismutase (SOD2); 
mtKATP, mitochondrial ATP-sensitive potassium channel; p47phox and p67phox, 
regulatory cytosolic subunits of NOX2; PYK, protein tyrosine kinase; RAAS, renin-
angiotensin-aldosterone system; 
membrane potential; mt
updated from [413, 415, 416]. Note to reviewers: This figure will be drawn by a 
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Table 1.  Studies on the effects of a diverse range of antioxidants on cardiac effects in cardiometabolic comorbidities  



















diet (HFO) for 12 
weeks. In vivo 




Reduction in the infarct 
size  
Reduction of oxidative 






















Reduction of infarct 




mitochondrial fission and 
cardiac oxidative stress 
 






10 mg/kg daily by 
gavage for 6 weeks 
 
Mice fed with 
western diet for 14 
weeks. 





Improvement of left 
ventricular fractional 
shortening; reduction of 
infarct size  
 
Improvement of redox 
regulation by decreasing 
iNOS expression and 
subsequently decreased 
of lipid peroxidation  
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coronary artery was 
occluded in pigs for 
45 minutes and then 
reperfused for 24 
hours 
Reduction in 
myocardial infarct size 
and improvement of left 
ventricular function in 
pigs after IRI 
Suppression of 
inflammation, apoptosis, 
and oxidative stress 
 












mg AC261066/100 ml 
in 0.1% 
dimethylsulfoxide/H2O 
for 6 weeks 
 
Obese (HFD-fed) 
wild-type mice  




Attenuation of infarct 




Decreased formation of 





Melatonin 4 mg/kg/day was 
administered in the 
drinking water for 16 
weeks 
A rat model of diet-
induced obesity 
IRI in ex Vivo Rat 
Hearts 
 
Reduction of infarct 
size and increased 
percentage recovery of 
functional performance 
of diet-induced obesity 
hearts. 
Increased activation of 
Akt, ERK42/44 and 






Simvastatin 3 mg/kg, orally for 3 
weeks 
Cholesterol fed 
rabbits received for 
6 weeks a diet 
enriched with 2 g of 
cholesterol.  
Reduction of infarct 
size 
Attenuation of oxidative 
and nitrosative stress 
Andreadou et al.  comorbidities and cardioprotection  79 
IRI in vivo 30 min 
ischemia and 180 
min reperfusion 
Andreadou I (2012) 
[158] 
 
Pravastatin 3 mg/kg orally for 3 
days 
Cholesterol fed 
rabbits received for 
6 weeks a diet 
enriched with 2 g of 
cholesterol. 
IRI in vivo 30 min 
ischemia and 180 
min reperfusion 
Reduction of infarct 
size 
Activation of eNOS and 
attenuation of nitro-
oxidative stress 
Andreadou I (2007) 
[159] 
 
Oleuropein  20 mg/kg daily, orally 
for 6 weeks and for 3 
weeks  
Cholesterol fed 
rabbits received for 
6 weeks a diet 
enriched with 2 g of 
cholesterol. 
IRI in vivo 30 min 
ischemia and 180 
min reperfusion 
Reduction of infarct 
size 
Protection against 
oxidative damage during 
ischemia-reperfusion, 
reduction of the protein 
carbonyl content and 
enhancement of SOD 
activity 






monoxime (IND)  
SB, 0.6 mg/kg, i.p., 
IND, 0.4 mg/kg, i.p., 
administered 24 h 
before the isolation of 
heart 
Rat by feeding 
high-fat diet for 6 
weeks  
IRI in Ex Vivo Rat 
Hearts 
 
Decrease of myocardial 
infarct size  
HSP acts on pathway of 
GSK-
significant role in 
cardioprotection 






Reduction in infarct 
size 
Inhibition of mPTP 
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IRI in Ex Vivo Rat 
Hearts 
 
Leng (2018) [219] Tubastatin A  
(HDAC6 
inhibitor) 





In vivo IRI; 45min 




infarct size and release 
of LDH and CK-MB 





Koka (2013) [229] Tadalafil (PDE5 
inhibitor) 
1mg/kg/day, i.p., for 
28days 
Type 2 diabetes 
(db/db mice) 
 
Ex vivo global IRI 
Reduction in infarct 
size  




of NADPH oxidase 
activity and expression 
of subunits pRac1 and 
gp91phox 
 
Yu (2017) [232] Melatonin 10 mg/kg orally for 5 





In vivo IRI; 30min 
ischemia and 180 
min reperfusion  
Improved cardiac 
function; reduced 
infarct size; reduced 
apoptosis 
Reduced mitochondrial 
oxidative stress and 
enhanced biogenesis; 
activated AMPK/PGC-
-SIRT3 signaling and 
increased expression of 
SOD2, NRF1 
and TFAM 






Reduced oxidative stress; 
activated Notch1 
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g/L HG, 4 ml/kg/h, 
i.v.) 
 




infarct size; reduced 
apoptosis 
signaling by increasing 
Trx activity while 
decreasing Txnip 
 
Yu (2015) [230] Melatonin 20 mg/kg/day orally T2D (HFD-STZ) rat 
model 
 







infarct size; reduced 
apoptosis 
Attenuation of oxidative 
stress and ER stress via 
activation of SIRT1 
signaling 
















Mao (2013) [222] Antioxidants 
(NAC and 
Allopurinol)   
 
Combination of NAC 
(1.5 g/kg/day) and 
ALP (100 mg/kg/day) 










infarct size and release 
of CK-MB 
Enhanced GSH/GSSG; 
Increased expression of 
HO-1 and HIF-  
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Nayak (2019) [239] Phloroglucinol 
(benzenetriol) 
100 mg/kg/day or 
200mg/kg/day 











parameters before I/R; 
reduced infarct size and 
release of CK-MB 
Increased GSH levels; 
decreased lipid 
peroxidation  
Xiao (2019) [243] Luteolin 
(polyphenol) 
100 mg/kg/day, i.g., 










function and myocardial 
viability 
Decreased oxidative 





antioxidant enzymes  
Yang (2015) [244] Luteolin 
(polyphenol) 











function and decreased 
LDH release 
Upregulation of eNOS 
and MnSOD; inhibition 
of mPTP 
Duan (2017) [242] Butin (plant 
flavonoid) 
10, 20 and 40 mg/kg 









reduced infarct size; 
decreased apoptosis 
Upregulation of Nrf2 and 
HO-1 via activation of 
AMPK/Akt/GSK3  
signaling pathway 
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Suchal (2017) [246] Kaempferol 
(plant flavonoid) 










parameters and cardiac 
function; decreased 
apoptosis 
Inhibition of the MAPK 
and AGE-RAGE 
pathways; attenuation of 














reduction in infarct size 
and apoptosis 
NO mediated induction 
of Trx-1, HO-1 and 
VEGF; activation of Mn-
SOD 
Fourny (2019) [234] Resveratrol 1 mg/kg/day orally for 
8 weeks 










expression of eNOS/ 
SIRT1 
Wu (2017) [245] Epigallocatechin-
3-gallate 
(EGCG) 





In vivo IRI; 30 min 
ischemia /2h 
reperfusion 






stress and fibrosis; 
increased expression of 
SIRT1and MnSOD 
 
The selection in this table is restricted to studies on ischemia/reperfusion injury (IRI) in metabolic comorbidities where antioxidants were 
administered exogenously.  Studies were excluded if full-text was not readily available or if experimental details and/or data were incompletely 
reported.  
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Abbreviations used in this Table: AGE, advanced glycation end-products; AMPK, AMP-activated protein kinase; eNOS, endothelial nitric oxide 
synthase; ERK,42/44 extracellular (signal) regulated kinase; GSK-3 , glycogen synthase kinase-3 ; HO-1, heme oxygenase-1; HSP, heat shock 
protein;   Keap1, Kelch-like ECH-associated protein1;  LDH,  lactate-dehydrogenase; MAPK, mitogen-activated protein kinase; MnSOD 
manganese-dependent superoxide dismutase; Nrf2, nuclear factor erythroid 2-related factor; RAGE, receptor of advanced glycation end-products 
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Table 2. Recent studies of a diverse range of antioxidants in pressure-overload hypertrophy models in vivo 
 





















Slight attenuation of 
hypertension development; 
reduced LV mass index; 
reduced myocyte cross 
sectional area  
 
H2 scavenges .OH and 










>0.6 mM H2 in 
saline by i.p. 








Dose-dependent attenuation of 
LV mass index; reduced 
collagen fraction; reduced LV 
natriuretic peptide expression 
 
Effects associated with 
reduced LV protein level of 
JAK and STAT3 and 
phospho-STAT3 
 






0.4, 2 or 10 
mg/kg daily by 









Prevention of cardiac 
hypertrophy; preservation of 
EF by echocardiography; 
reduced collagen fraction  
 
Reduced ROS production and 
preservation of mitochondrial 
membrane potential in 
isolated cardiac myocytes 










200 mg/kg daily 






Attenuation of LV mass index; 
preservation of EF and other 
echocardiographic indices. 
 
Effects associated with 
reduced activation of TAK1, 
p38 MAPK and JNK1/2 


















Attenuation of LV mass index; 
reduced LV echocardiographic 
dimensions; reduced LV 
natriuretic peptide expression; 
reduced collagen fraction  
 
Increased activity of SOD and 
catalase. In vitro, 
antihypertrophic effects of 
isorhyncophylline are Nrf2 
dependent.  
 






10 or 20 mg/kg 
daily by gastric 






Attenuation of cardiac index; 
reduced LV natriuretic peptide 




In vitro, suppression of 
phenylephrine induced 
cardiac myocyte hypertrophy 
and reduced ROS generation, 
abolished by Nrf2 
knockdown. Enhanced eNOS 
activity and NO generation 
 
 













Attenuation of cardiac 
hypertrophy; reduced 
natriuretic peptide expression; 
preserved EF; improved 
echocardiographic indices; 
reduced collagen fraction; 
enhanced autophagy markers 
 
 
In vitro, suppression of Ang 
II-induced myocyte 
hypertrophy; autophagy 
effects of oridonin P21-
dependent 
 






5, 10 or 20 mg/kg 





Attenuation of cardiac 
hypertrophy at 10 or 20 mg/kg; 
reduced myocyte cross 
 
In vitro, suppression of Ang 
II-induced myocyte 
hypertrophy; inhibition of 
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compound 
[thiosulfinate]) 
injection for 4 
weeks 
sectional area; reduced 
natriuretic peptide expression; 
reduced expression of 
autophagy markers 
 
autophagy was via activation 


























Improved recovery of 
contractile function after 20 
min global ischemia ex vivo; 
reduced plasma superoxide 









50 mg/kg daily by 
gavage for 1 
week before and 






Marked attenuation of LV 
hypertrophy; attenuation of 
echocardiographic changes; 
reduced LV ROS detection; 





induced myocyte hypertrophy 
attenuated; preservation of 
mitochondrial membrane 










5 mg/kg or 40 
mg/kg daily by 
i.p injection for 4 





mouse (not stated 
if thoracic or 
abdominal) 
 
No attenuation of LV 
hypertrophy; attenuation of 
natriuretic peptide expression; 
dose-dependent reduction of 




Specific effect on fibrosis; in 
vitro, no attenuation of Ang 
II-induced myocyte 
hypertrophy; attenuation of 
TGF-beta1 stimulated cardiac 
fibroblast proliferation; 
inhibition of Smad signalling 
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20 mg/kg daily by 
i.p. injection, 
from 1 week 




mouse (not stated 
if thoracic or 
abdominal) 
 
Attenuation of LV 
hypertrophy; improved 
ejection fraction and 
attenuation of other 
echocardiographic changes; 
attenuation of LV natriuretic 
peptide expression; reduced 
LV ROS production; increased 




In vitro, attenuation of 
phenylephrine-induced 
myocyte hypertrophy; 
reduction in ERK1/2, p38 
MAPK, JNK1/2 and mTOR 
phosphorylation in vivo and 
in vitro. No additive effect in 








5, 10 or 20 mg/kg 
daily by gavage 















related to GSK-3 activation as 
a result of proteasome 
activation in vivo (and in Ang 









50 umol/kg daily 





Attenuation of blood pressure 
increase and LV hypertrophy 
in wild type but not SIRT3 
knockout mice; reduced 
 
In vitro, attenuation of Ang II 
induced myocyte hypertrophy 
and natriuretic peptide 
expression plus improved 
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myocardial ROS production in 
wild type but not SIRT3 
knockout mice 
 
mitochondrial function in 









50 mg/kg daily by 
gavage starting 7 
days before Ang 
II treatment 
 
Ang II infusion by 
minipump for 28 
days, rat 
 
Non-significant attenuation of 
blood pressure rises; 
attenuation of cardiac 
hypertrophy, myocyte cross-
section area and collagen 
fraction;  
 
Decreased cardiac NADPH 
oxidase activity and Nox 2 
and Nox 4 expression; 
concentration-dependent 
antihypertrophic effect in 










Orally in diet 4 
g/kg, equivalent 
to 146 mg/kg 









Ang II infusion by 
minipump for 14 
days, mouse 
 












In vitro activation of AMPK; 
inhibition of p70S6K and 
NFAT; no effect on SIRT1 
expression. In vivo, no effects 
of resveratrol on 
physiological hypertrophy 
induced by exercise training 
(rat)  
 
Articles specifically examining the effects of antioxidants on pressure overload hypertrophy and published in the date range 01 January 2015 to 
07 November 2020 were retrieved from the PubMed database. The selection in this table is restricted to studies of pressure-overload models in 
vivo where antioxidants were administered exogenously.  Studies were excluded if full-text was not readily available or if experimental details 
and/or data were incompletely reported.  
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Abbreviations used in this Table: AMPK, AMP-activated protein kinase; Ang II, angiotensin II; EF, LV ejection fraction; ERK, extracellular 
(signal) regulated kinase; GSK, glycogen synthase kinase; JAK, Janus kinase;  JNK, c-Jun N-terminal kinase; MAPK, mitogen activated protein 
kinase; mPTP, mitochondrial permeability transition pore; mTOR, mammalian target of rapamycin; NFAT, nuclear factor of activated T-cells; 
Nox, NADPH oxidase; Nrf2, nuclear factor erythroid 2-related factor; SIRT, sirtuin; STAT, signal transducer and activator of transcription; 
TAK1, transforming growth factor beta-activated kinase; TGF, transforming growth factor.  
 
